Roger Hawley Net Worth

The estimated Net Worth of Roger Hawley is at least $7.14 Million dollars as of 11 April 2019. Roger Hawley owns over 454,545 units of Dare Bioscience Inc stock worth over $3,080,557 and over the last 14 years Roger sold DARE stock worth over $4,059,064.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Roger Hawley DARE stock SEC Form 4 insiders trading

Roger has made over 13 trades of the Dare Bioscience Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Roger bought 454,545 units of DARE stock worth $500,000 on 11 April 2019.

The largest trade Roger's ever made was buying 454,545 units of Dare Bioscience Inc stock on 11 April 2019 worth over $500,000. On average, Roger trades about 34,678 units every 109 days since 2010. As of 11 April 2019 Roger still owns at least 944,956 units of Dare Bioscience Inc stock.

You can see the complete history of Roger Hawley stock trades at the bottom of the page.

What's Roger Hawley's mailing address?

Roger's mailing address filed with the SEC is C/O ZOGENIX, INC., 12671 HIGH BLUFF DR., SUITE 200, SAN DIEGO, CA, 92130.

Insiders trading at Dare Bioscience Inc

Over the last 7 years, insiders at Dare Bioscience Inc have traded over $0 worth of Dare Bioscience Inc stock and bought 594,545 units worth $703,000 . The most active insiders traders include William H Rastetter, Roger Hawley, and Cheryl R Blanchard. On average, Dare Bioscience Inc executives and independent directors trade stock every 152 days with the average trade being worth of $969,110. The most recent stock trade was executed by Roger Hawley on 11 April 2019, trading 454,545 units of DARE stock currently worth $500,000.

What does Dare Bioscience Inc do?

daré bioscience (nasdaq: dare) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s reproductive health. we are driven by a mission to identify, develop and bring to market a diverse portfolio of novel therapies that expand treatment options, improve outcomes and facilitate convenience for women. we are initially focused on the areas of contraception, vaginal health and fertility. our lead product candidate, ovaprene, is a non-hormonal, monthly contraceptive ring that is currently in clinical studies.

Complete history of Roger Hawley stock trades at Zogenix Inc and Dare Bioscience Inc

Dare Bioscience Inc executives and stock owners

Dare Bioscience Inc executives and other stock owners filed with the SEC include:

• John A. Fair,
  Chief Strategy Officer
• Lisa Walters-Hoffert,
  Chief Financial Officer
• Robin Steele,
  Independent Director
• Gregory Matz,
  Independent Director
• Susan Kelley,
  Independent Director
• Steve Hall,
  Independent Director
• Jessica Grossman,
  Independent Director
• Cheryl Blanchard,
  Independent Director
• John Fair,
  Chief Business Officer
• Jame O'Neill,
  Principal Accounting Officer, Controller, Assistant Treasurer
• Lisa Walters-Hoffert,
  Chief Financial Officer
• Gregg Beloff,
  Principal Financial Officer
• Sabrina Johnson,
  President, Chief Executive Officer, Secretary, Director
• William Rastetter,
  Independent Chairman of the Board
• John Katsilometes,
  Controller
• Mary Jarosz,
  Global Head of Regulatory Affairs
• Dr. David Friend,
  Chief Scientific Officer
• MarDee J. Haring-Layton,
  VP of Accounting & Fin.
• Mark Walters,
  VP of Operations
• Roger Hawley,
  Director
• Mar Dee Haring Layton,
  Chief Accounting Officer
• Sophia Nnenna Ononye Onyia,
  Director